By working with bacterial cellulose, we unite natural biocompatibility with reproducible production to develop off-the-shelf, reliable small-diameter grafts. Our aim is to offer a regenerative, accessible solution that advances the future of vascular care.
Read more
ArtiFex Medical GmbH, founded in 2020 in Vienna as a spin-off from University Hospital Basel, develops a bacterial-cellulose graft platform with reproducible manufacturing and natural biocompatibility. Our team brings together expertise in vascular biology, material science and medtech development to bring reliable small-diameter grafts to market.
Read more
We use bacterial cellulose, a naturally produced material with a biologically structured nanofibrillar network as a basis for our patented graft technology. Its smooth blood-contacting surface is designed to support early tissue integration and a low inflammatory response.
Read more
Each year, more than 850,000 coronary artery bypass surgeries and millions of hemodialysis patients rely on vascular grafts for life-sustaining blood flow. Yet small-diameter synthetic grafts (<6 mm) are not approved for coronary or dialysis access use due to insufficient long-term patency.
Read more